Enhancing autophagy or increasing longevity by administration of urolithins

Patent metadata

Field	Value
Publication number	US-11931336-B2
Application number	US-202117324490-A
Country	US
Kind code	B2
Filing date	May 19, 2021
Priority date	Jun 27, 2012
Publication date	Mar 19, 2024
Grant date	Mar 19, 2024

Abstract

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

First claim

We claim:

1. A method of treating a disease or condition selected from the group consisting of sarcopenia, sarcopenia of aging, osteoarthritis, muscular atrophy, muscle disuse atrophy, skeletal muscular atrophy, cardiac deterioration, cardiac deterioration with aging, negative consequences linked to aging, improving activity during aging, reducing age-related cataracts, improving balance or coordination, and frailty, comprising administering to a subject in need thereof a therapeutically effective amount of a urolithin, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the disease or condition is sarcopenia.

3. The method of claim 1 , wherein the disease or condition is sarcopenia of aging.

4. The method of claim 1 , wherein the disease or condition is osteoarthritis.

5. The method of claim 1 , wherein the disease or condition is muscular atrophy.

6. The method of claim 1 , wherein the disease or condition is muscle disuse atrophy.

7. The method of claim 1 , wherein the disease or condition is skeletal muscular atrophy.

8. The method of claim 1 , wherein the disease or condition is cardiac deterioration.

9. The method of claim 1 , wherein the disease or condition is cardiac deterioration of aging.

10. The method of claim 1 , wherein the disease or condition is negative consequences linked to aging.

11. The method of claim 1 , wherein the disease or condition is improving activity during aging.

12. The method of claim 1 , wherein the disease or condition is reducing age-related cataracts.

13. The method of claim 1 , wherein the disease or condition is improving balance or coordination.

14. The method of claim 1 , wherein the disease or condition is frailty.

15. The method of claim 1 , wherein the urolithin is administered orally.

16. The method of claim 1 , wherein the urolithin is selected from the group consisting of urolithin A, urolithin B, and any combination thereof.

17. The method of claim 1 , wherein the urolithin is urolithin A.

18. The method of claim 1 , wherein the urolithin is urolithin B.

19. The method of claim 1 , wherein the subject is a human.

20. The method of claim 1 , wherein the urolithin is administered orally; the urolithin is urolithin A; and the subject is a human.

Assignees

• Amazentis Sa

Inventors

• Rinsch Christopher L
• Blanco-Bose William
• Schneider Bernard
• Mouchiroud Laurent
• Ryu Dongryeol
• Andreux Penelope
• Auwerx Johan

Classifications

• A61P17/18

  Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00) · CPC title

• A61K31/7016

  Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032) · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/525

  Isoalloxazines, e.g. riboflavins, vitamin B2 · CPC title

• A61K31/122

  having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin · CPC title